Inhibition of mutant BRAF splice variant signaling by next‐generation, selective RAF inhibitors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Vemurafenib and dabrafenib block MEK‐ERK 1/2 signaling and cause tumor regression in the majority of advanced‐stage BRAF V600E melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors. Next‐generation RAF inhibitors, such as PLX 7904 (PB 04), effectively inhibit RAF signaling in BRAF V600E melanoma cells without paradoxical effects in wild‐type cells. Furthermore, PLX 7904 blocks the growth of vemurafenib‐resistant BRAF V600E cells that express mutant NRAS. Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX 7904 and its clinical analog, PLX 8394 (PB 03), in BRAF V600E splice variant‐mediated vemurafenib‐resistant cells. We show that paradox‐breaker RAF inhibitors potently block MEK‐ERK 1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX 4720‐resistant cells harboring distinct BRAF V600E splice variants. These data support the further investigation of paradox‐breaker RAF inhibitors as a second‐line treatment option for patients failing on vemurafenib or dabrafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“The RAF inhibitors, vemurafenib and dabrafenib, are FDA approved for the treatment for BRAFV600E-harboring melanoma, but most patients who respond will ulti- mately develop progressive disease (Chapman et al., 2011; Flaherty et al., 2010; Hauschild et al., 2012; Sosman et al., 2012).”
BackgroundRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 2×
“This acquired/secondary resistance is frequently driven by ERK1/2 pathway re-activation and is mediated by the expression of alternative splice forms of BRAFV600E, secondary mutations in forms of RAS, or amplification of BRAFV600E (Nazarian et al., 2010; Pouli- kakos et al., 2011; Shi et al., 2012).”
Background
Cited by
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
“Another second-generation RAF inhibitor is the “paradox breaker” PLX8394 that also effectively inhibits CRAF and BRAF (Basile et al. 2014; Choi et al. 2014; Zhang et al. 2015).”
BackgroundNew perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0274-5 · Cited by 195
Tutuka, C. S. A., Andrews, M. C., Mariadason, J. M., Ioannidis, P., Hudson, C., Cebon, J., & Behren, A. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0684-x · Cited by 58
Metadata
- Authors
- Basile, K. J., Le, K., Hartsough, E. J., & Aplin, A. E.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2014-02-10
- Volume
- 27
- Issue
- 3
- Pages
- 479-484
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2002028874
- Cited by
- 53
- References
- 2
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.